Anti-adalimumab and anti-certolizumab antibodies titers after discontinuation of adalimumab: Two case reports

Mariapaola Marino, Umberto Basile, Valentina Grossi, Maria Infantino, Mariangela Manfredi, Francesca Gulli, Francesca Li Gobbi, Arianna Damiani, Fabiola Atzeni, Maurizio Benucci

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Tumor necrosis factor (TNF)-α plays a key role in the pathogenesis of chronic inflammatory disorders; the discovery of TNF-blockers, neutralizing its biological activities, opened the way to a new efficacious therapeutic strategy. Unfortunately, the immunogenicity of anti-TNF drugs may trigger an adverse immune response with the occurrence of anti-drug antibodies (ADAs) impairing drug efficacy and safety. The increase of drug doses to overcome the effect of ADAs gives rise to many adverse effects inducing to the treatment discontinuation
Lingua originaleEnglish
pagine (da-a)950-953
Numero di pagine4
RivistaClinical Chemistry and Laboratory Medicine
Volume2019
DOI
Stato di pubblicazionePubblicato - 2019

Keywords

  • TNF
  • adalimumab
  • anti-TNF drugs
  • certolizumab
  • immunogenicity

Fingerprint Entra nei temi di ricerca di 'Anti-adalimumab and anti-certolizumab antibodies titers after discontinuation of adalimumab: Two case reports'. Insieme formano una fingerprint unica.

Cita questo